Skip to main content
Midas Edge

TENAX THERAPEUTICS, INC.

For the period ended Dec 31, 2025. Filed Mar 10, 2026.

View on SEC.gov

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2025 · Filed Mar 10, 2026

TENX$1.69-5.1%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits
Contents

CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY

(Amounts in thousands, except share data)

Preferred Stock · Common Stock
Number of Shares · Amount · Number of Shares · Amount · Additional paid-in capital · Accumulated deficit · Total stockholders' equity
Balance at December 31, 2023210$-298,281$-$305,351$(297,253)$8,098
Public offering sale of common stock, warrants, and prefunded warrants, net of offering costs of $8,416--1,871,921-100,303-100,303
Exercise of pre-funded warrants--1,178,707-1-1
Exercise of warrants--12,000-68-68
Stock split and fractional shares issued--59,997----
Stock-based compensation expense----1,125-1,125
Net loss-----(17,602)(17,602)
Balance at December 31, 2024210$-3,420,906$-$406,848$(314,855)$91,993
Public offering sale of common stock, warrants, and prefunded warrants, net of offering costs of $1,746--378,346-23,216-23,216
Exercise of pre-funded warrants--2,538,799-12-12
Exercise of warrants--2,976,079115,285-15,286
Stock-based compensation expense----19,163-19,163
Net loss-----(52,599)(52,599)
Balance at December 31, 2025210$-9,314,130$1$464,524$(367,454)$97,071
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.